Pharmacokinetic Study With Repeated Doses of Stalevo
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to show that higher minimum concentration values are obtained following repeated doses of Stalevo 4 times daily compared to lecodopa/carbidopa treatment with corresponding dosing regimen.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
30 Years to 72 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Written informed consent obtained
Male or female patients with idiopathic Parkinson's disease with either a stable drug response or mild and predictable end-of-dose wearing-off symptoms.
Hoehn and Yahr stage 1-2.5 performed during the "ON" state.
Treatment with 3-5 daily doses of levodopa/DDCI ± entacapone with a total daily levodopa dose in the range of 300-600 mg.
Unchanged levodopa/DDCI ± entacapone and other antiparkinsonian medication (dopamine agonists, monoamine oxidase B (MAO-B) inhibitor, amantadine and/or anticholinergics with doses recommended by the manufacturer), if any, for at least 2 weeks prior to the first treatment period.
Age within 30-72 years, inclusive.
Secondary or atypical parkinsonism.
Patients with moderate to marked wearing-off symptoms or any unpredictable "OFF"-periods.
Patients with treatment-related peak-dose dyskinesia.
Change in dose strength, daily dose or dosing frequency of any medicinal products used to treat other medical conditions than Parkinson's disease within 2 weeks.
Use of any iron preparations or other chelating agents.
Patients with a history of a laboratory abnormality consistent with, or clinically significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, neurological or psychiatric disorder or any other major concurrent illness, which may influence the outcome of the study.
History of neuroleptic malignant syndrome (NMS) and/or non-traumatic rhabdomyolysis, malignant melanoma, narrow-angle glaucoma or pheochromocytoma.
Any abnormalities in laboratory values, vital signs or electrocardiogram (ECG) with clinical relevance.
Patients using any antiparkinsonian drugs for rescue medication (including soluble levodopa formulations).
Concomitant treatment with apomorphine, MAO-A inhibitors or non-selective MAO inhibitors.
Known hypersensitivity to active substances or to any of the excipients of the study drugs.
Participation in other drug studies within 60 days prior to study entry
Unsuitable veins for repeated venopuncture.
Blood donation or loss of significant amount of blood within 60 days prior to the screening.